dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Bairaktari, Eleni Th | en |
dc.contributor.author | Kalef-Ezra, J. A. | en |
dc.contributor.author | Nikolaides, C. | en |
dc.contributor.author | Seferiadis, C. | en |
dc.contributor.author | Fountzilas, George | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Bairaktari, Eleni Th | en |
dc.creator | Kalef-Ezra, J. A. | en |
dc.creator | Nikolaides, C. | en |
dc.creator | Seferiadis, C. | en |
dc.creator | Fountzilas, George | en |
dc.date.accessioned | 2018-06-22T09:54:16Z | |
dc.date.available | 2018-06-22T09:54:16Z | |
dc.date.issued | 1995 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42271 | |
dc.description.abstract | The levels of soluble interleulkin-2 receptors (sIL-R2) were measured in the serum of 52 patients with epithelial ovarian carcinoma as well as in 25 age and sex-matched normal controls. The mean serum level of sIL-2R was increased in 37 patients (71.2%). Comparison of these levels to those of normal controls showed a highly statistically significant difference (p< 0.001). Serum sIL-2R levels were not related to histology, clinical stage or the presence of ascites (p=0.58, p=0.32 and p=0.67, respectively), nor did they follow disease activity or response to chemotherapy. However patients with higher pretreatment sIL-2R levels (more than 1200 U/ml) were found to have a longer survival (p<0.02), possibly explained by the presence of activated lymphocytes and a better immune surveillance. We conclude that the serum level of sIL-2R: a) is elevated in ovarian cancer patients, b) has no relationship with histological subtypes, tumor burden or the presence of ascites, c) cannot serve as a valuable tumor marker for the monitoring of patient treatment, and d) has a prognostic value for survival. | en |
dc.language.iso | eng | en |
dc.source | International Journal of Biological Markers | en |
dc.subject | Article | en |
dc.subject | Human | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Ca-125 antigen | en |
dc.subject | Cancer survival | en |
dc.subject | Ovarian cancer | en |
dc.subject | Ovarian neoplasms | en |
dc.subject | Retrospective studies | en |
dc.subject | Clinical article | en |
dc.subject | Treatment outcome | en |
dc.subject | Prognosis | en |
dc.subject | Carcinoma | en |
dc.subject | Interleukin-2 | en |
dc.subject | Receptors | en |
dc.subject | Interleukin 2 receptor | en |
dc.subject | Biological | en |
dc.subject | Tumor markers | en |
dc.subject | Middle age | en |
dc.subject | Neoplasm proteins | en |
dc.subject | Ovary carcinoma | en |
dc.subject | Ca 125 | en |
dc.subject | Ascites | en |
dc.subject | Solubility | en |
dc.subject | Soluble interleukin-2 receptors | en |
dc.subject | Tumor marker | en |
dc.title | Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients | en |
dc.type | info:eu-repo/semantics/article | |
dc.description.volume | 10 | |
dc.description.issue | 2 | |
dc.description.startingpage | 75 | |
dc.description.endingpage | 80 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |